Indonesia’s BPOM Achieves WHO Listing, Signaling Regulatory Excellence

Ahead of its 25th anniversary on January 31, the Indonesian Food and Drug Authority (BPOM) has been officially recognized as a World Health Organization (WHO) – listed Authority (WLA) for its vaccine regulatory system. The announcement, made by the WHO on December 21, 2025, signifies international trust in Indonesia’s regulatory framework and governance.

A Milestone Achievement

Indonesia is the first middle-income country with a standalone regulatory authority to achieve this recognition, joining an elite group of 38 predominantly developed nations, including the United States, the United Kingdom and Australia WHO. This status confirms that BPOM’s regulatory decisions meet global standards and can be relied upon internationally.

The WHO WLA Framework

The WLA framework is the WHO’s global benchmark for regulatory excellence. It’s a public registry of authorities that have undergone rigorous evaluation and demonstrated consistent performance in ensuring the quality, safety, and efficacy of vaccines. The framework promotes transparency, harmonization of standards, and regulatory reliance, allowing countries to trust each other’s decisions and reduce unnecessary duplication WHO.

BPOM’s Journey to WLA Status

BPOM’s path to becoming a WLA was the result of sustained reform. The journey began in 2018, when BPOM achieved WHO Maturity Level 3 for vaccines, indicating a functional regulatory system. The focus then shifted toward reaching Maturity Level 4, which reflects a stable, integrated, and advanced authority. This transition required a shift from administrative compliance toward evidence-based governance.

Over several years, BPOM strengthened core regulatory functions, including clinical trial oversight, laboratory testing, lot release, and post-market surveillance. Throughout this process, independence, transparency, and scientific integrity remained paramount.

Rigorous Evaluation Process

The evaluation process was extensive. BPOM conducted a comprehensive self-assessment using the WHO Global Benchmarking Tool, followed by peer reviews and assessments by international experts. The process culminated in an evaluation by the WHO Technical Advisory Group on Listed Authorities, an independent body ensuring only regulators with consistent, high-level performance are granted WLA status.

Global Significance and Impact

Indonesia’s recognition carries global significance, signaling that regulatory excellence isn’t limited to high-income countries. Strong, credible regulatory systems can be built in diverse resource settings and trusted globally. This contributes to a more inclusive and resilient global regulatory landscape.

WLA recognition reinforces BPOM’s role as an enabler, particularly as global health risks increase and supply chains remain fragile. Regulatory credibility is a strategic asset underpinning public health, innovation, and economic competitiveness.

Benefits for Academia and Industry

Internationally recognized regulatory standards enhance the credibility of Indonesian research and clinical trials, opening opportunities for global collaboration. Predictable and transparent regulatory pathways encourage investment in research and development, technology transfer, and high-value manufacturing.

This is especially significant for Indonesia’s pharmaceutical and vaccine industries as they compete in international markets. Products regulated by a globally recognized authority face fewer barriers and gain faster acceptance, positioning Indonesian manufacturers as reliable partners in global supply chains.

Heightened Responsibility and Future Outlook

WLA recognition brings heightened responsibility. BPOM will be judged not only by its high standards but too by its ability to maintain them consistently. Maintaining impartiality and avoiding regulatory capture will be crucial as engagement with industry and innovation ecosystems increases.

As stated by Taruna Ikrar, head of the Food and Drug Monitoring Agency, this achievement contributes to a more inclusive and resilient global regulatory landscape The Jakarta Post.